News
Adding pertuzumab to standard of care improved survival by 17% in patients with early-stage HER2-positive breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback